METHYLENE BLUE INJECTION, USP SOLUTION Kanada - İngilizce - Health Canada

methylene blue injection, usp solution

mylan pharmaceuticals ulc - methylene blue - solution - 10mg - methylene blue 10mg - antidotes

METHYLENE BLUE INJECTION, USP LIQUID Kanada - İngilizce - Health Canada

methylene blue injection, usp liquid

hospira healthcare ulc - methylene blue - liquid - 1% - methylene blue 1% - antidotes

METHYLENE BLUE SOLUTION 1% LIQUID Kanada - İngilizce - Health Canada

methylene blue solution 1% liquid

rougier pharma division of ratiopharm inc - methylene blue - liquid - 1% - methylene blue 1% - gastric function

METHYLENE BLUE INJECTION USP LIQUID Kanada - İngilizce - Health Canada

methylene blue injection usp liquid

omega laboratories limited - methylene blue - liquid - 10mg - methylene blue 10mg - antidotes

METHYLENE BLUE INJECTION USP SOLUTION Kanada - İngilizce - Health Canada

methylene blue injection usp solution

alveda pharmaceuticals inc - methylene blue - solution - 10mg - methylene blue 10mg - antidotes

COLYTE- peg-3350 and electrolytes powder, for solution ABD - İngilizce - NLM (National Library of Medicine)

colyte- peg-3350 and electrolytes powder, for solution

meda pharmaceuticals - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750) - polyethylene glycol 3350 240 g in 4 l - colyte® with flavor packs is indicated for bowel cleansing prior to colonoscopy or barium enema x-ray examination. colyte is contraindicated in the following conditions: colyte® (co-light) with flavor packs (peg-3350 & electrolytes for oral solution) read this instructions for use before you start taking colyte. this information does not take the place of talking with your healthcare provider about your medical condition or your treatment. how should i take colyte? colyte can be taken with or without a flavor pack. if you use a flavor pack, complete steps 1 through 8. if you do not use a flavor pack, throw away the flavor packs and complete steps 4 through 8. step 1:  remove the cap from the colyte bottle. step 2:  tear open 1 flavor pack of your choice and pour contents into the colyte bottle. throw away the unused flavor pack. step 3:  replace the cap on the colyte bottle. shake the colyte bottle well to mix the contents of the flavor pack into the powder. step 4:  remove the cap from the colyte bottle.

EQUATE SUPPORT ADVANCED LUBRICANT- polyethylene glycol, and propylene glycol solution/ drops ABD - İngilizce - NLM (National Library of Medicine)

equate support advanced lubricant- polyethylene glycol, and propylene glycol solution/ drops

wal-mart stores inc - polyethylene glycol 400 (unii: b697894sgq) (polyethylene glycol 400 - unii:b697894sgq), propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - polyethylene glycol 400 4 mg in 1 ml - uses - for the temporary relief of burning and irritation due to dryness of the eye stop use and ask a doctor if - you feel eye pain - changes in vision occur - redness or irritation of the eye(s) gets worse, persists or lasts more than 72 hours directions - shake well before using. - instill 1 or 2 drops in the affected eye(s) as needed.

EQUATE LUBRICANT EYE- polyethylene glycol 400, and propylene glycol solution/ drops ABD - İngilizce - NLM (National Library of Medicine)

equate lubricant eye- polyethylene glycol 400, and propylene glycol solution/ drops

wal-mart stores inc - polyethylene glycol 400 (unii: b697894sgq) (polyethylene glycol 400 - unii:b697894sgq), propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - polyethylene glycol 400 4 mg in 1 ml - uses for the temporary relief of burning and irritation due to eye dryness. do not use - if solution changes color or becomes cloudy - if you are sensitive or allergic to any ingredient in this product stop use and ask a doctor if - you experience eye pain - changes in vision occur - redness or irritation of the eye(s) gets worse or lasts more than 72 hours directions - put 1 or 2 drops in the affected eye/s as needed

CLEARLAX- polyethylene glycol powder, for solution ABD - İngilizce - NLM (National Library of Medicine)

clearlax- polyethylene glycol powder, for solution

rebel distributors corp - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g - use(s) • relieves occasional constipation (irregularity) • generally produces a bowel movement in 1 to 3 days use(s) • relieves occasional constipation (irregularity) • generally produces a bowel movement in 1 to 3 days

MOVIPREP- polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid kit ABD - İngilizce - NLM (National Library of Medicine)

moviprep- polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid kit

physicians total care, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 100 g in 1 l - moviprep® is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. moviprep is contraindicated in patients who have had a severe hypersensitivity reaction to any of its components. pregnancy category c. animal reproduction studies have not been performed with moviprep.  it is also not known if moviprep can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. moviprep should be given to a pregnant woman only if clearly needed. because many drugs are excreted in human milk, caution should be exercised when moviprep is administered to a nursing woman. the safety and effectiveness of moviprep in pediatric patients has not been established. of the 413 patients in clinical studies receiving moviprep, 91 (22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years of age.  no overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other repo